Showing 21-30 of 2962 results for "".
Buying a Laser, Circa 2024
https://practicaldermatology.com/issues/april-2024/buying-a-laser-circa-2024/24439/Joel Schlessinger, MD, shares his experiences with the process of adding new equipment to his dermatology practice, culminating in the purchase of the Sciton mJoule and JouleX lasers. He also highlights the importance of planning early for tax deductions and emphasizes the value of a supportive netwCSF 2022 Highlights
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/csf-2022-highlights/20162/Joel Schlessinger, MD says the 2022 Cosmetic Surgery Forum was a success. The unique format of the meeting encourages presenters and audience members to interact and engage in lively discussions that allow attendees to leave the meeting with ideas they can use in their practices immediately.Make Your Mark: Formulate a Product Line
https://practicaldermatology.com/topics/practice-management/make-your-mark-formulate-a-product-line/20023/Dispensing skincare offers benefits to your practice and your patients. Joel Schlessinger, MD discusses his journey with his son to developing their own product formulation and offers insights and encourages colleagues to use their unique talents to do the same.CSF 2016 Highlights from the Founder
https://practicaldermatology.com/topics/skin-cancer-photoprotection/csf-2016-highlights-from-the-founder/18711/Cosmetic Surgery Forum Founder and Practical Dermatology® Chief Surgical Editor Joel Schlessinger, MD talks about CSF 2016. What sets the meeting apart? How has it evolved in 8 years? And what did he learn from this year's program? Find out.Pearls from CSF 2022
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/pearls-from-csf-2022/20163/It’s not just the attendees who learned at this year’s Cosmetic Surgery Forum. Meeting founder Joel Schlessinger, MD discusses some of the presentations that were most impactful to him. From presentations about the effectiveness of new technology to discussions about the usefulness of hyaluronidaseBurnout: Is Personal Happiness the Answer?
https://practicaldermatology.com/series/the-practical-dermatology-podcast/burnout-is-personal-happiness-the-answer/18191/Physician burnout remains a conversation, and the pandemic dramatically changed the landscape for dermatologists—for better and for worse. Omaha, NE-based Joel Schlessinger, MD, who serves as Chief Cosmetic Surgery Editor of Practical Dermatology® speaks with Las Vegas-based dermatologist H.L. GreenDermWireTV: The Year in Review - 2023!
https://practicaldermatology.com/topics/psoriasis/dermwiretv-the-year-in-review-2023/20229/Practical Dermatology® Co-Chief Medical Editor, Joel Schlessinger, MD, shares his thoughts on some of the best products and approvals of 2023 as well as the potential of new JAK inhibitors to treat alopecia areata, vitiligo, psoriasis, and atopic dermatitis. Our new contributor, Andrew Mastro, PA, t- Telehealth Webinar from Cosmetic Surgery Forum Explores Best Practiceshttps://practicaldermatology.com/news/telehealth-webinar-available-from-cosmetic-surgery-forum/2460325/As dermatologists deal with the evolving COVID-19 crisis, they are increasingly searching for guidance on the proper use of telemedicine. Joel Schlessinger, MD, Founder of Cosmetic Surgery Forum, brought together George Hruza, MD, past president of the AAD, and Antoanella Calame, MD, founder of the…
- CSF Unveils New Faculty, Sessions for 2014 Meetinghttps://practicaldermatology.com/news/20140724-csf_unveils_new_faculty_sessions/2459158/Cosmetic Surgery Forum has added new faculty members and educational sessions to its agenda. New to the podium this year will be Joel Cohen, MD, Ellen Marmur, MD, Gerald Goldberg, MD, Michael Greenberg, MD, Sabrina Fabi, MD, and Laurin Council, MD. New sessions include "Polishing Your Neurotoxin Te…
- Allergan to Acquire Kytherahttps://practicaldermatology.com/news/allergan-to-acquire-kythera/2458927/Allergan has entered into a definitive agreement to acquire Kythera Biopharmaceuticals in a cash and stock transaction valued at $75 per share, or approximately $2.1 billion. Once the transaction is complete, Kythera’s recently approved Kybella (deoxycholic acid) will be part of an aesthetic portfo…